Sponsors and Collaborators
Mayo Clinic

Contact
Fernando C Fervenza, M.D., Ph.D.
507-266-7083
[email protected]

Lori A Riess
507-266-1047
[email protected]


Continue Reading

Eligibility

  • Age >18 years
  • Proteinuria > 5g/24h despite ACEi and/or ARB treatment for > 3 months
  • Estimated or quantified  GFR > 40 ml/min/1.73m2 while taking ACEi/ARB therapy
  • Resistant to cyclosporine (CSA) are excluded but patients who initially responded to CSA but relapsed off CSA are eligible for the study

Principal Investigator
Fernando C. Fervenza, M.D., Ph.D., Mayo Clinic

ClinicalTrials.gov Identifier
NCT01180036